ChemoCentryx Inc
NASDAQ:CCXI
Intrinsic Value
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CCXI.
ChemoCentryx Inc's market capitalization is 3.7B USD.
CCXI stock price is 51.99 USD.
CCXI.
CCXI. Open DCF Valuation
CCXI. Open Relative Valuation
CCXI.
CCXI's Altman Z-Score is equal to 2.39.
CCXI has positive Gross Profit for the last twelve months.
CCXI's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -101% to -116%, and is approaching profitability.
CCXI's ROE (Return on Equity) has significantly decreased in the last 3 years from -30% to -47%, and is approaching profitability.
CCXI's Revenue has grown by an exceptional 72% over the past 12 months.
CCXI has negative Operating Income for the last twelve months.
CCXI has negative Net Income for the last twelve months.
CCXI's ROE (Return on Equity) for the past 12 months is negative and is equal to -47%.
CCXI's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -116%.
CCXI's long-term assets (419m USD) exceed its long-term liabilties (183m USD).
CCXI has negative Free Cash Flow for the last twelve months.
CCXI's D/E (Debt to Equity) is very low and is equal to 0.02.
CCXI has negative three-year average ROE (Return on Equity): -56%. The company is not efficient at transforming stockholders' equity into net income.
CCXI has negative three-year average ROIC (Return on Invested Capital): -164%. The company is not efficient at using invested capital to generate operating income.
CCXI's short-term assets (345m USD) exceed its short-term liabilties (76m USD).
CCXI has negative Net Debt. This means that the company has more cash and short-term investments (329m USD) than debt (4m USD).
CCXI doesn't generate enough operating income (-132m USD) to safely cover interest payments on its debt (2m USD).
Fundamental Analysis
ChemoCentryx Inc
Balance Sheet Decomposition
ChemoCentryx Inc
| Current Assets | 345.2m |
| Cash & Short-Term Investments | 328.6m |
| Receivables | 4.9m |
| Other Current Assets | 11.6m |
| Non-Current Assets | 74.2m |
| Long-Term Investments | 17.6m |
| PP&E | 55.2m |
| Other Non-Current Assets | 1.5m |
| Current Liabilities | 76.1m |
| Accounts Payable | 7.6m |
| Accrued Liabilities | 27.7m |
| Other Current Liabilities | 40.7m |
| Non-Current Liabilities | 106.8m |
| Long-Term Debt | 4m |
| Other Non-Current Liabilities | 102.8m |
Earnings Waterfall
ChemoCentryx Inc
|
Revenue
|
37.3m
USD
|
|
Cost of Revenue
|
-19.1m
USD
|
|
Gross Profit
|
18.2m
USD
|
|
Operating Expenses
|
-149.9m
USD
|
|
Operating Income
|
-131.7m
USD
|
|
Other Expenses
|
-1.4m
USD
|
|
Net Income
|
-133.1m
USD
|
Free Cash Flow Analysis
ChemoCentryx Inc
CCXI Profitability Score
Profitability Due Diligence
ChemoCentryx Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
ChemoCentryx Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
CCXI Solvency Score
Solvency Due Diligence
ChemoCentryx Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
ChemoCentryx Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CCXI Price Targets Summary
ChemoCentryx Inc
Ownership
CCXI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CCXI Price
ChemoCentryx Inc
| Average Annual Return | 118.12% |
| Standard Deviation of Annual Returns | 79.87% |
| Max Drawdown | -86% |
| Market Capitalization | 3.7B USD |
| Shares Outstanding | 71 919 696 |
| Percentage of Shares Shorted | 11.08% |
CCXI News
Last Important Events
ChemoCentryx Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
ChemoCentryx Inc
Company Profile
ChemoCentryx Inc
Country
Industry
Market Cap
Dividend Yield
Description
ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The firm's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The firm is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.
You don't have any saved screeners yet
